Sabinsa Receives Patent for OcuFors®

EAST WINDSOR, N.J.The Japan Patent Office has awarded Sabinsa Corporation a patent for the companys water-soluble form of naturally available diterpenes derived from Coleus forskolii. The patent covers both the method for solubilizing diterpenes using randomly methylated β-cyclodextrin molecules and applications in glaucoma. This is the 73rd global patent for Sabinsa, which said it will market the product under the brand name OcuFors®.

OcuFors is the first naturally derived pharmaceutical product approved by the Drug Controller General of India, and Sabinsa is seeking approval as a drug for glaucoma treatment in several other countries. OcuFors® has been found effective for treatment of open-angle glaucoma and reducing the intraocular pressure better than Timolol, a non-selective beta blocker used in glaucoma treatment.

This patent represents the 73^rd in Sabinsa Corporations robust global patent portfolio. In 2010, Sabinsa earned a Chinese patent for a process that makes the forskolin molecule 6000-times more water soluble.